Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase…











